Omecamtiv mecarbil (OM) is a novel, selective cardiac myosin activator that improves cardiac function, ventricular volumes, and NT-proBNP in patients with HFrEF.

Omecamtiv mecarbil with highest affinity to the pre powerstroke state of myosin, increasing the force produced during each cycle of cardiac contraction.

**METHODS**

Multinational, double-blind, placebo-controlled, event-driven trial

Randomization 1:1 (6 Jan 2017 - 9 Jul 2019)

Stratification by patient vs. region

**GALACTIC-HF**

**BASELINE CHARACTERISTICS FROM THE CARDIOVASCULAR OUTCOMES TRIAL OF OMECAMTIV MECAR Bil (GALACTIC-HF)**

John R. Teerlink, Rafael Diaz, G. Michael Felker, John J. V. McMurray, Marco Metra, Scott D. Solomon, Jason C. Leggi, Claire Varin, Christopher E. Kurtz, Fady I. Malik, Siddique A. Abbas, San Francisco Veterans Affairs Medical Center and University of California San Francisco, San Francisco; CA; Estudios Clínicos Latino America, Rosario, Argentina; Duke University and Duke Clinical Research Institute, Durham, NC; University of Glasgow, Glasgow, UK; University of Brescia, Italy; Brigham and Women’s Hospital and Harvard Medical School, Boston, MA; Weimers, Thousand Oaks, CA; Sanner, Suresnes, France; Cytokinetics, Inc., South San Francisco, CA.

Omecamtiv mecarbil (OM) is a novel, selective cardiac myosin activator that improves cardiac function, ventricular volumes, and NT-proBNP in patients with HFrEF.

Omecamtiv mecarbil binds with highest affinity to the pre powerstroke state of myosin, increasing the force produced during each cycle of cardiac contraction.

**ENROLLED PATIENT POPULATION**

Overall, 8,256 patients were enrolled

998 pg/mL Median NT-proBNP

25% Inpatient

27% Mean EF 44% NYHA Class III

67% ACEi/ARB/ARNi 94% BB 77% MRA

Those randomized as inpatients had higher prevalence of atrial fibrillation/flutter and NYHA Class III, higher NT-proBNP, and decreased renal function.

**CONCLUSION**

GALACTIC-HF has enrolled a well-treated population from both inpatient and outpatient settings, which will provide guidance on implementation of this potentially life-saving therapy.

**CV Outcomes Trial for Omecamtiv Mecarbil Enrolls 8,256 Patients With HFrEF**

GALACTIC-HF is testing the hypothesis that omecamtiv mecarbil improves clinical outcomes in patients with HFrEF enrolled from both inpatient and outpatient settings.

**Results are anticipated Q4 of 2020.**

For more information, email john.teerlink@ucsf.edu